MAOB and depressive symptom measurement: New formulations of levodopa (intraduodenal, inhaled, subcutaneous, etc.)(86%), antidyskinetic drugs (79%), therapies for non-motor symptoms (dementia, depression, impulse control disorders [ICD], fatigue, pain, etc.)(79%), therapies to increase levodopa bioavailability (camicinal, DA-9701, VY-AADC01, etc.)(78%) and new symptomatic drugs (MAO-B, COMTI, agonists, etc.)(70%) were considered to be quite or very useful in the treatment of PD with a trend of increase by 2030 (Supplementary Figure S3A).